There are currently 2876 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
NCT06534892
Recruiting
The purpose of this study is: * To investigate the optimal timing for revaccination after the initial RSVPreF3 OA vaccine dose, * To evaluate the long-term immune persistence and safety up to 5 consecutive RSV seasons (approximately 60 months) of a single dose of RSVPreF3 OA vaccine, * To give the opportunity to participants who received only placebo in the RSVOA=ADJ- 006 study, to receive a dose of the RSVPreF3 OA vaccine and collect additional safety information.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
08/06/2025
Locations: GSK Investigational Site, Houston, Texas
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
NCT06236724
Recruiting
To learn if asciminib can help to control CML. The safety and effects of this drug will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Chronic Myeloid Leukemia
Register for Updates
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
NCT05653271
Recruiting
ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of CD20-expressing B-cell malignancies. The ACE1831-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, and efficacy of ACE1831 in patients with CD20-expressing Non-Hodgkin lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL, Primary Mediastinal Large B Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Burkitt Lymphoma, High-grade B-cell Lymphoma
Register for Updates
Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy
NCT06569368
Recruiting
To learn if adding metronidazole to standard therapy can decrease populations of Fusobacterium nucleatum (F. nucleatum) and other anaerobes (small organisms that cause infections) in participants with rectal cancer receiving neoadjuvant therapy, compared to neoadjuvant therapy alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Rectal Adenocarcinoma
Register for Updates
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247
Recruiting
This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AML).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/06/2025
Locations: Houston Methodist Hospital, Houston, Texas +1 locations
Conditions: Leukemia
Register for Updates
An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis
NCT06836232
Recruiting
This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Recurrent Pericarditis (RP). Approximately 30 patients will take VTX2735. The study consists of a 30-day Screening Period (to see if a participant qualifies for the study), a 6-week Open Label Treatment period (a participant receives active Dose A), a 7-week Extension Treatment period (a participant meets criteria for continuing and receives active Dose A) and a 14-day Follow-Up Period.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/06/2025
Locations: Local Site #840001, Houston, Texas
Conditions: Recurrent Pericarditis
Register for Updates
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)
NCT06687967
Recruiting
This is a parallel, Phase 3, 2-arm study for treatment. The purpose of this study is to measure improvement in pruritus with dupilumab subcutaneous injections compared with placebo injections in male and female participants aged at least 18 years with LSC. Study details include: The study duration will be up to 40 weeks. The treatment duration will be up to 24 weeks. The follow-up duration after treatment will be 12 weeks. The number of visits will be 6.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: MedCare Pharma - Houston - Cypress Creek Parkway- Site Number : 8400014, Houston, Texas
Conditions: Lichen Simplex Chronicus
Register for Updates
Transcutaneous Vagus Nerve Stimulation for Attention and Memory
NCT06723743
Recruiting
This clinical trial aims to evaluate whether transcutaneous auricular vagus nerve stimulation (taVNS), a non-invasive brain stimulation method, can improve attention and memory in veterans with traumatic brain injury (TBI) and depression and/or posttraumatic stress disorder (PTSD). The study seeks to answer two main questions: 1. Can active taVNS improve attention and memory compared to sham (placebo) stimulation? 2. Does taVNS affect heart rate variability (HRV)? taVNS delivers a gentle elect... Read More
Gender:
ALL
Ages:
Between 25 years and 64 years
Trial Updated:
08/06/2025
Locations: Michael E. DeBakey VA Medical Center, Houston, Texas +1 locations
Conditions: Traumatic Brain Injury (TBI) Patients
Register for Updates
Patient Priorities for Survivorship Care in Older Breast Cancer Survivors
NCT06478589
Recruiting
The objective of this study is to adapt the Patient Priorities Care (PPC) framework to breast cancer survivorship via a user-centered approach, through an iterative process in which patients and their physicians help to refine and modify the intervention. A second objective is to evaluate the feasibility and effectiveness of the adapted PPC framework in breast cancer survivorship for older adults.
Gender:
FEMALE
Ages:
Between 65 years and 100 years
Trial Updated:
08/06/2025
Locations: UT Physicians Family Medicine Bayshore, Houston, Texas +1 locations
Conditions: Breast Cancer Survivorship
Register for Updates
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
NCT06699212
Recruiting
The goal of this clinical trial is to learn if ASP-1929 photoimmunotherapy (PIT) in combination with pembrolizumab works to treat recurrent squamous cell cancer of the head and neck (HNSCC) with no distant metastases. It will also learn about the safety of ASP-1929 PIT in combination with pembrolizumab. Researchers will compare ASP-1929 PIT in combination with pembrolizumab to pembrolizumab alone or pembrolizumab plus chemotherapy (carboplatin or cisplatin, plus 5-fluorouracil or paclitaxel or... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: University of Texas, MD Anderson Cancer Center, Houston, Texas
Conditions: Recurrent Head and Neck Squamous Cell Carcinoma
Register for Updates
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT06161025
Recruiting
This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Houston Methodist Hospital, Houston, Texas +3 locations
Conditions: Solid Cancer
Register for Updates
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
NCT06564818
Recruiting
The purpose of this study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in participants with MDD.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
08/06/2025
Locations: Zillan Clinical Research, Houston, Texas
Conditions: Major Depressive Disorder
Register for Updates